Karin Von Wachenfeldt

This inventor holds 16 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: Cantargia Ab, Medimmune Limited, Amplio Pharma Ab. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karin Von Wachenfeldt. Retrieved from https://idiyas.com/inventor/karin-von-wachenfeldt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 7)

% Patents Active = 68.8

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 13)

Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 95(Granted Patents)

Company Filing History:

Truly Translational Sweden Ab

patent

Years Active: 2011-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12398213 - Methods of treating IL1RAP associated cancers with anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies (2025-08-26),

2. 12209131 - Anti-IL1RAP antibody compositions (2025-01-28),

3. 12043666 - Anti-IL1RAP antibody (2024-07-23),

4. 11883405 - Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy (2024-01-30),

5. 11479610 - Anti-IL1RAP antibody (2022-10-25),

6. 11236172 - Methods of producing an IL-1 RAP antibodies (2022-02-01),

7. 10752692 - Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof (2020-08-25),

8. 10703723 - Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease (2020-07-07),

9. 10562971 - Method of detection of IL1RAP on cells expressing the protein (2020-02-18),

10. 10287357 - Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies (2019-05-14),

11. 10100119 - Anti-human interleukin-1 receptor accessory protein antibody and its use for treating cancer (2018-10-16),

12. 9796783 - Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof (2017-10-24),

13. 9587027 - Methods for binding members of interleukin-4 receptor α (IL-4Rα) (2017-03-07),

14. 8877189 - Binding members for interleukin-4 receptor alpha (IL-4Rα) - 173 (2014-11-04),

15. 8092804 - Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 (2012-01-10),

Title: Karin Von Wachenfeldt: Innovator in Antibody Research

Introduction

Karin Von Wachenfeldt is an accomplished inventor based in Lund, Sweden. With a remarkable portfolio of 14 patents, she has made significant contributions to the field of biomedicine, particularly in the development of therapeutic antibodies. Her innovative work continues to influence medical research and treatment methodologies.

Latest Patents

Among her recent innovations, one of her notable patents involves an Anti-IL1RAP antibody. This invention pertains to an antibody or an antigen-binding fragment with specificity for the interleukin-1 receptor accessory protein (IL1RAP). The patent also encompasses a polynucleotide encoding the antibody, along with a vector and recombinant host cell featuring said polynucleotide. Furthermore, it outlines a method for producing the antibody, emphasizing its potential use in medical treatments for diseases associated with IL-1α, IL-1β, IL-33, IL-36α, IL-36β, and IL-36γ signaling pathways.

Another significant patent from Karin is a pharmaceutical composition that represents a combination of methotrexate and novobiocin, along with their pharmaceutically acceptable salts. This innovation aims to enhance therapeutic effectiveness in treating autoimmune diseases, indicating her commitment to addressing pressing medical challenges through her inventive work.

Career Highlights

Karin has garnered experience and expertise working with prominent organizations such as Cantargia AB and MedImmune Limited. Her impressive career highlights reflect her dedication to advancing research and development in the pharmaceutical industry, particularly in antibody therapy and autoimmune disease treatment.

Collaborations

Throughout her career, Karin has collaborated with esteemed colleagues, including Kjell Sjöström and Helena Ågerstam. These partnerships have provided valuable insights and shared knowledge, further amplifying the impact of her inventions within the scientific community.

Conclusion

Karin Von Wachenfeldt exemplifies the spirit of innovation through her groundbreaking patents and contributions to biomedicine. Her work not only aids in understanding complex diseases but also offers new therapeutic avenues for treatment, showcasing her invaluable role as an inventor in the modern medical landscape.

Profile summary based on public USPTO records.